Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.09.002
M. Perréard, I. Huet, C. Legrais, E. Babin
{"title":"French campaign for laryngectomees’ quality of life","authors":"M. Perréard, I. Huet, C. Legrais, E. Babin","doi":"10.1016/j.anorl.2025.09.002","DOIUrl":"10.1016/j.anorl.2025.09.002","url":null,"abstract":"","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 75-76"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/S1879-7296(26)00014-1
{"title":"Thanks to reviewers","authors":"","doi":"10.1016/S1879-7296(26)00014-1","DOIUrl":"10.1016/S1879-7296(26)00014-1","url":null,"abstract":"","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Page 77"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145982070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.07.003
L. de Villars , M. Douet , C. Aussedat
Introduction
HEC® phenazone-tannin-witch hazel ointment is widely used in the treatment of epistaxis, with few adverse effects. Anaphylactic shock after packing with HEC® ointment has, to the authors’ knowledge, never previously been reported.
Case report
A 53 year-old male presented with massive epistaxis requiring packing after cauterization. After packing with HEC® ointment, the patient experienced grade 5 anaphylactic shock, requiring admission to intensive care. The outcome was ultimately favorable.
Conclusion
Potential allergy to the ingredients of HEC® ointment should be ascertained before application, to avoid serious reactions.
{"title":"Anaphylactic shock induced by HEC® ointment: A CARE case report","authors":"L. de Villars , M. Douet , C. Aussedat","doi":"10.1016/j.anorl.2025.07.003","DOIUrl":"10.1016/j.anorl.2025.07.003","url":null,"abstract":"<div><h3>Introduction</h3><div>HEC® phenazone-tannin-witch hazel ointment is widely used in the treatment of epistaxis, with few adverse effects. Anaphylactic shock after packing with HEC® ointment has, to the authors’ knowledge, never previously been reported.</div></div><div><h3>Case report</h3><div>A 53 year-old male presented with massive epistaxis requiring packing after cauterization. After packing with HEC® ointment, the patient experienced grade 5 anaphylactic shock, requiring admission to intensive care. The outcome was ultimately favorable.</div></div><div><h3>Conclusion</h3><div>Potential allergy to the ingredients of HEC® ointment should be ascertained before application, to avoid serious reactions.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 56-57"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144805077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.08.003
A. Ferney , T. Ferney , A. Lazard , S. Schmerber , E. Gay , R. Quatre
Aim
This study aimed to assess long-term progression of residual tumor and facial function after primary partial resection of large vestibular schwannoma.
Materials and methods
This retrospective study was performed in a tertiary reference center between January 2008 and December 2021. Patients with vestibular schwannoma exceeding 25 mm on the long axis underwent partial tumor resection, leaving a residual fragment, and were followed up for at least 3 years. The residue was confirmed on MRI at 6 months. Facial grade was assessed on the House-Brackmann classification at the immediate postoperative time-point and at 1 year.
Results
Fifty-seven patients were included: 10 (17%) showed tumor regrowth, at a mean 53 ± 25.5 months. Forty (70%) showed facial grades ≤ III at the immediate postoperative time, and 51 (89%) at 1 year. Mean residual tumor size was 13.6 ± 7.2 mm in patients with regrowth and 7.4 ± 5 mm in those without (P < 0.01). On multivariate analysis, only residual tumor size was significantly associated with regrowth (OR = 1.263; 95% CI [1.050–1.677]; P = 0.04). ROC analysis identified a 6.5 mm threshold for residual tumor size, beyond which risk of regrowth increased, with 90% sensitivity, 53% specificity and 0.78 AUC.
Conclusion
Partial resection of large vestibular schwannoma provided satisfactory control and only mild postoperative facial palsy. Small residual tumor size was the main factor for success.
{"title":"Long-term follow-up of residual tumor and facial function after partial resection of vestibular schwannoma","authors":"A. Ferney , T. Ferney , A. Lazard , S. Schmerber , E. Gay , R. Quatre","doi":"10.1016/j.anorl.2025.08.003","DOIUrl":"10.1016/j.anorl.2025.08.003","url":null,"abstract":"<div><h3>Aim</h3><div>This study aimed to assess long-term progression of residual tumor and facial function after primary partial resection of large vestibular schwannoma.</div></div><div><h3>Materials and methods</h3><div>This retrospective study was performed in a tertiary reference center between January 2008 and December 2021. Patients with vestibular schwannoma exceeding 25<!--> <!-->mm on the long axis underwent partial tumor resection, leaving a residual fragment, and were followed up for at least 3 years. The residue was confirmed on MRI at 6 months. Facial grade was assessed on the House-Brackmann classification at the immediate postoperative time-point and at 1 year.</div></div><div><h3>Results</h3><div>Fifty-seven patients were included: 10 (17%) showed tumor regrowth, at a mean 53<!--> <!-->±<!--> <!-->25.5 months. Forty (70%) showed facial grades<!--> <!-->≤<!--> <!-->III at the immediate postoperative time, and 51 (89%) at 1 year. Mean residual tumor size was 13.6<!--> <!-->±<!--> <!-->7.2<!--> <!-->mm in patients with regrowth and 7.4<!--> <!-->±<!--> <!-->5<!--> <!-->mm in those without (<em>P</em> <!--><<!--> <!-->0.01). On multivariate analysis, only residual tumor size was significantly associated with regrowth (OR<!--> <!-->=<!--> <!-->1.263; 95% CI [1.050–1.677]; <em>P</em> <!-->=<!--> <!-->0.04). ROC analysis identified a 6.5<!--> <!-->mm threshold for residual tumor size, beyond which risk of regrowth increased, with 90% sensitivity, 53% specificity and 0.78 AUC.</div></div><div><h3>Conclusion</h3><div>Partial resection of large vestibular schwannoma provided satisfactory control and only mild postoperative facial palsy. Small residual tumor size was the main factor for success.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 19-23"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.06.008
P. Toulemonde , F. Giraudet , J. Macario , V. Krause , C. Vincent
Objective
This study aimed to evaluate the psychometric function curve and signal-to-noise ratio (SNR) loss values during the “Vocale Rapide dans le Bruit” (VRB) speech-in-noise test with speech level presentations at 65 dB SPL (VRB65) and 45 dB SPL (VRB45) in normal-hearing subjects.
Materials and methods
Adult normal-hearing subjects underwent an audiological evaluation including tympanometry, pure-tone audiometry, speech recognition threshold in silence and speech-in-noise audiometry following the recommended protocol (65 dB SPL, VRB65), followed by a second series of tests with a lower sentence presentation level (45 dB SPL, VRB45).
Results
Among the 29 normal-hearing subjects, there was no significant variation in the psychometric function curves or SNR loss values for VRB65 or VRB45.
Conclusion
The “Vocale Rapide dans le Bruit” speech-in-noise test is a relevant tool for assessing auditory difficulties in noisy environments. In normal-hearing subjects, presenting sentences at different intensity levels did not show a significant difference. This was an essential prerequisite for its use at various signal presentation levels, which could enable the evaluation of the functional state of high- and low-threshold auditory nerve fibers. This, in turn, would refine clinical diagnosis and improve the management of hearing disorders associated with hidden hearing loss.
目的：研究正常听力受试者在语音水平为65dB SPL （VRB65）和45dB SPL （VRB45）的情况下进行“快速声跳”（Vocale Rapide dans le Bruit， VRB）语音噪声测试时的心理测量函数曲线和信噪比损失值。材料和方法：成年正常听力受试者按照推荐方案（65dB SPL, VRB65）进行听力学评估，包括鼓室测听、纯音测听、无声语音识别阈值测听和噪声语音测听，然后进行第二组较低句子呈现水平的测试（45dB SPL, VRB45）。结果：29名听力正常受试者中，VRB65和VRB45的心理功能曲线和信噪比损失值无显著差异。结论：“Vocale Rapide dans le Bruit”噪声语音测试是评估噪声环境下听觉困难的有效工具。在听力正常的被试中，不同强度的句子呈现没有显著差异。这是在各种信号呈现水平下使用该方法的必要前提，从而能够评估高阈值和低阈值听神经纤维的功能状态。反过来，这将改进临床诊断并改善与隐性听力损失相关的听力障碍的管理。
{"title":"Speech audiometry in noise: Signal noise ratio loss values according speech signal level presentation in normal hearing subjects","authors":"P. Toulemonde , F. Giraudet , J. Macario , V. Krause , C. Vincent","doi":"10.1016/j.anorl.2025.06.008","DOIUrl":"10.1016/j.anorl.2025.06.008","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to evaluate the psychometric function curve and signal-to-noise ratio (SNR) loss values during the “Vocale Rapide dans le Bruit” (VRB) speech-in-noise test with speech level presentations at 65<!--> <!-->dB SPL (VRB65) and 45<!--> <!-->dB SPL (VRB45) in normal-hearing subjects.</div></div><div><h3>Materials and methods</h3><div>Adult normal-hearing subjects underwent an audiological evaluation including tympanometry, pure-tone audiometry, speech recognition threshold in silence and speech-in-noise audiometry following the recommended protocol (65<!--> <!-->dB SPL, VRB<sub>65</sub>), followed by a second series of tests with a lower sentence presentation level (45<!--> <!-->dB SPL, VRB<sub>45</sub>).</div></div><div><h3>Results</h3><div>Among the 29 normal-hearing subjects, there was no significant variation in the psychometric function curves or SNR loss values for VRB<sub>65</sub> or VRB<sub>45</sub>.</div></div><div><h3>Conclusion</h3><div>The “Vocale Rapide dans le Bruit” speech-in-noise test is a relevant tool for assessing auditory difficulties in noisy environments. In normal-hearing subjects, presenting sentences at different intensity levels did not show a significant difference. This was an essential prerequisite for its use at various signal presentation levels, which could enable the evaluation of the functional state of high- and low-threshold auditory nerve fibers. This, in turn, would refine clinical diagnosis and improve the management of hearing disorders associated with hidden hearing loss.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 14-18"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.12.001
X. Dubernard , J. Ortega Solis , M.-J. Fraysse , S. Tronche , V. Darrouzet , T. Mom
Introduction
Menière's disease is a fluctuating pressure pathology featuring successive hydropic episodes of varying frequency and intensity. The accumulation of these episodes and of the certain treatments can induce vestibular deficit and episodes of chronic instability. Vestibular rehabilitation aims to limit everyday impact by developing compensation and adaptation. How and when should it be introduced?
Material and methods
A systematic review of the literature for the period 1963–2022 was conducted by an expert group comprising of ENT physicians and vestibular physiotherapists. For each reference, the level of evidence was recorded as 1, 2, 3, 4 or expert opinion. Recommendations were graded A, B or C according to the methodological quality of the underlying studies; when there was no evidence-based consensus, an “expert opinion” was formulated based on the group members’ clinical practices.
Results
Eighteen articles were selected via 4 scientific search engines (PubMed, Google Scholar, PEDro, Science Direct) and 3 keywords “Rehabilitation”, “Vestibular rehabilitation”, and “Menière's disease”.
Conclusion
Vestibular rehabilitation is recommended in Menière's disease in case of uncompensated spontaneous progressive vestibular deficit or surgical or medical vestibular suppression (gentamicin injection). Rehabilitation should await a period of 3 months’ stability, and be adapted to the individual complaint. It should be supervised by a rehabilitation professional: self-rehabilitation is not recommended.
{"title":"Guidelines of the French Society of ENT (short version) on the role and modalities of vestibular rehabilitation in Menière's disease","authors":"X. Dubernard , J. Ortega Solis , M.-J. Fraysse , S. Tronche , V. Darrouzet , T. Mom","doi":"10.1016/j.anorl.2025.12.001","DOIUrl":"10.1016/j.anorl.2025.12.001","url":null,"abstract":"<div><h3>Introduction</h3><div>Menière's disease is a fluctuating pressure pathology featuring successive hydropic episodes of varying frequency and intensity. The accumulation of these episodes and of the certain treatments can induce vestibular deficit and episodes of chronic instability. Vestibular rehabilitation aims to limit everyday impact by developing compensation and adaptation. How and when should it be introduced?</div></div><div><h3>Material and methods</h3><div>A systematic review of the literature for the period 1963–2022 was conducted by an expert group comprising of ENT physicians and vestibular physiotherapists. For each reference, the level of evidence was recorded as 1, 2, 3, 4 or expert opinion. Recommendations were graded A, B or C according to the methodological quality of the underlying studies; when there was no evidence-based consensus, an “expert opinion” was formulated based on the group members’ clinical practices.</div></div><div><h3>Results</h3><div>Eighteen articles were selected via 4 scientific search engines (PubMed, Google Scholar, PEDro, Science Direct) and 3 keywords “Rehabilitation”, “Vestibular rehabilitation”, and “Menière's disease”.</div></div><div><h3>Conclusion</h3><div>Vestibular rehabilitation is recommended in Menière's disease in case of uncompensated spontaneous progressive vestibular deficit or surgical or medical vestibular suppression (gentamicin injection). Rehabilitation should await a period of 3 months’ stability, and be adapted to the individual complaint. It should be supervised by a rehabilitation professional: self-rehabilitation is not recommended.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 50-55"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145890324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.07.002
M. Cachi-Pouyenne, R. Haddad, D. Robert, J. Michel, A. Giovanni, A. Mattei
Background
In France, speech therapists are not authorized to perform fiberoptic endoscopic or other instrumental evaluations of swallowing to detect silent penetration or aspiration and to guide rehabilitation. Even so, regulations allow local cooperation protocols to be set up.
Aims
To assess the feasibility of the first interprofessional cooperation protocol for fiberoptic endoscopic evaluation of swallowing by speech therapists in hospitalized patients.
Method
Between April 2023 and November 2024, 100 patients from various departments in our hospital underwent bedside evaluation of swallowing by a speech therapist, including functional fiberoptic endoscopy.
Results
There were no severe adverse effects and no additional discomfort associated with fiberoptic endoscopic evaluation of swallowing performed by a speech therapist as compared to head-and-neck surgery residents (95% CI, 0.114–2.922; P > 0.05). After checking the assessment report, the delegating ENT physicians did not alter the speech therapist's recommendations.
Conclusion
This first interprofessional cooperation protocol between ENT specialists and speech therapists for fiberoptic endoscopic evaluation of swallowing in France contributed to management of hospital patients with swallowing disorder, without adverse effects.
{"title":"Delegating fiberoptic endoscopic evaluation of swallowing to speech therapists: Feedback from 20 months’ experience","authors":"M. Cachi-Pouyenne, R. Haddad, D. Robert, J. Michel, A. Giovanni, A. Mattei","doi":"10.1016/j.anorl.2025.07.002","DOIUrl":"10.1016/j.anorl.2025.07.002","url":null,"abstract":"<div><h3>Background</h3><div>In France, speech therapists are not authorized to perform fiberoptic endoscopic or other instrumental evaluations of swallowing to detect silent penetration or aspiration and to guide rehabilitation. Even so, regulations allow local cooperation protocols to be set up.</div></div><div><h3>Aims</h3><div>To assess the feasibility of the first interprofessional cooperation protocol for fiberoptic endoscopic evaluation of swallowing by speech therapists in hospitalized patients.</div></div><div><h3>Method</h3><div>Between April 2023 and November 2024, 100 patients from various departments in our hospital underwent bedside evaluation of swallowing by a speech therapist, including functional fiberoptic endoscopy.</div></div><div><h3>Results</h3><div>There were no severe adverse effects and no additional discomfort associated with fiberoptic endoscopic evaluation of swallowing performed by a speech therapist as compared to head-and-neck surgery residents (95% CI, 0.114–2.922; <em>P</em> <!-->><!--> <!-->0.05). After checking the assessment report, the delegating ENT physicians did not alter the speech therapist's recommendations.</div></div><div><h3>Conclusion</h3><div>This first interprofessional cooperation protocol between ENT specialists and speech therapists for fiberoptic endoscopic evaluation of swallowing in France contributed to management of hospital patients with swallowing disorder, without adverse effects.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 7-10"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sex differences in cancer survival are well-established but understudied in oropharyngeal squamous cell carcinoma (OPSCC). We evaluated the impact of sex on OPSCC survival with emphasis on geographic variation. A systematic review through June 2025 identified 84 studies (N = 451,136) from the United States (n = 47) and non-United States cohorts (n = 37). Meta-analyses assessed hazard ratios, proportions, and means. Most patients were male (80.8%; mean age 59.9 years). HPV-positive OPSCC was more prevalent in the US (73.8%) than non-US countries (44.0%, P < 0.0001). US males had improved overall (HR = 1.13 [1.07–1.19]) and cause-specific survival (HR = 1.11 [1.01–1.21]) than females. Non-US females had better OS (HR = 0.86 [0.77–0.95]) and CSS (HR = 0.63 [0.43–0.92]) than males. No significant differences were observed in other survival measures. Sex appears to influence OPSCC survival, with differing trends between US and non-US populations. These geographic differences likely reflect differences in HPV status. Further research stratified by sex and HPV status is needed to clarify these relationships and guide tailored interventions.
{"title":"Sex and survival in oropharyngeal squamous cell carcinoma: A systematic review and meta-analysis","authors":"W.B. Chun , E.S. Chernov , K. Chen , S.A. Nguyen , A.R. Marrero-Gonzalez , M.N. Stevens , A.V. Drawdy , A.E. Kejner","doi":"10.1016/j.anorl.2025.11.005","DOIUrl":"10.1016/j.anorl.2025.11.005","url":null,"abstract":"<div><div>Sex differences in cancer survival are well-established but understudied in oropharyngeal squamous cell carcinoma (OPSCC). We evaluated the impact of sex on OPSCC survival with emphasis on geographic variation. A systematic review through June 2025 identified 84 studies (N<!--> <!-->=<!--> <!-->451,136) from the United States (<em>n</em> <!-->=<!--> <!-->47) and non-United States cohorts (<em>n</em> <!-->=<!--> <!-->37). Meta-analyses assessed hazard ratios, proportions, and means. Most patients were male (80.8%; mean age 59.9<!--> <!-->years). HPV-positive OPSCC was more prevalent in the US (73.8%) than non-US countries (44.0%, <em>P</em> <!--><<!--> <!-->0.0001). US males had improved overall (HR<!--> <!-->=<!--> <!-->1.13 [1.07–1.19]) and cause-specific survival (HR<!--> <!-->=<!--> <!-->1.11 [1.01–1.21]) than females. Non-US females had better OS (HR<!--> <!-->=<!--> <!-->0.86 [0.77–0.95]) and CSS (HR<!--> <!-->=<!--> <!-->0.63 [0.43–0.92]) than males. No significant differences were observed in other survival measures. Sex appears to influence OPSCC survival, with differing trends between US and non-US populations. These geographic differences likely reflect differences in HPV status. Further research stratified by sex and HPV status is needed to clarify these relationships and guide tailored interventions.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 30-39"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145696537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.anorl.2025.11.001
J. Frija , E. Béquignon , L. Laccourreye , I. Atallah , F. Gagnadoux , R. Tamisier
Objectives
To update practices for setting up, follow-up and indications in hypoglossal nerve stimulation in France.
Methods
Analysis of Medline, Cochrane and Embase databases (1970–2024), with assessment of techniques, follow-up modalities, results and side effects. Six physicians (3 ENT specialists, 3 pulmonologists, all involved in hypoglossal stimulation) took part in a work-group between January 2024 and January 2025.
Results
Only one implant, Inspire IV, is available in France, indicated for non-obese (BMI < 32 kg/m2) patients with moderate-to-severe obstructive sleep apnea-hypopnea syndrome (OSAHS) (apnea/hypopnea index [AHI] 15–50/h), and failure of or contraindications for continuous positive airway pressure (CPAP) or mandibular advancement device (MAD). Prior drug-induced sleep endoscopy (DISE) is mandatory. Studies show a 68% decrease in AHI, 70% decrease in oxygen desaturation index (ODI) at 12 months, and improvements in somnolence and quality of life, which seem stable at 36 months. About 25% of patients experience side effects, which are mostly transient. Final set-up requires polysomnography; follow-up requires clinical examination and/or poly(somno)graphy.
Conclusion
This new alternative treatment in France should be proposed for symptomatic patients with failure of CPAP or MAD, rigorously screened in multidisciplinary centers.
{"title":"Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: Update on French practices and position paper of the SFRMS, SPLF and SFORL sleep medicine work-group","authors":"J. Frija , E. Béquignon , L. Laccourreye , I. Atallah , F. Gagnadoux , R. Tamisier","doi":"10.1016/j.anorl.2025.11.001","DOIUrl":"10.1016/j.anorl.2025.11.001","url":null,"abstract":"<div><h3>Objectives</h3><div>To update practices for setting up, follow-up and indications in hypoglossal nerve stimulation in France.</div></div><div><h3>Methods</h3><div>Analysis of Medline, Cochrane and Embase databases (1970–2024), with assessment of techniques, follow-up modalities, results and side effects. Six physicians (3 ENT specialists, 3 pulmonologists, all involved in hypoglossal stimulation) took part in a work-group between January 2024 and January 2025.</div></div><div><h3>Results</h3><div>Only one implant, Inspire IV, is available in France, indicated for non-obese (BMI<!--> <!--><<!--> <!-->32<!--> <!-->kg/m<sup>2</sup>) patients with moderate-to-severe obstructive sleep apnea-hypopnea syndrome (OSAHS) (apnea/hypopnea index [AHI] 15–50/h), and failure of or contraindications for continuous positive airway pressure (CPAP) or mandibular advancement device (MAD). Prior drug-induced sleep endoscopy (DISE) is mandatory. Studies show a 68% decrease in AHI, 70% decrease in oxygen desaturation index (ODI) at 12<!--> <!-->months, and improvements in somnolence and quality of life, which seem stable at 36<!--> <!-->months. About 25% of patients experience side effects, which are mostly transient. Final set-up requires polysomnography; follow-up requires clinical examination and/or poly(somno)graphy.</div></div><div><h3>Conclusion</h3><div>This new alternative treatment in France should be proposed for symptomatic patients with failure of CPAP or MAD, rigorously screened in multidisciplinary centers.</div></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"143 1","pages":"Pages 40-49"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号